



National
Library
of Medicine NLM

My NC
[Sign In] [Regis]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Book

Search for

Limits Preview/Index History Clipboard Details

Display Show

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Cell Stress Chaperones. 1998 Mar;3(1):6-11.

Related Articles, Links

Definition of extracellular localized epitopes of Hsp70 involved in an NK immune response.

Botzler C, Li G, Issels RD, Multhoff G.

GSF-Institute of Clinical Hematology and Klinikum Grosshadern, Med. Klinik III, Munich, Germany.

In order to define extracellular localized epitopes of Hsp70 on human tumor cells which are accessible to the immune system, six commercially available Hsp70-specific monoclonal antibodies (mAb) with different recognition sites were examined by immunological approaches. The recognition pattern of these antibodies was analyzed on purified recombinant Hsp70 proteins (rHsp70, Hsc70, DnaK), on lysates of Hsp70-expressing colon carcinoma cells (CX+) and on lysates of M21 rat-1 cells that overexpress human Hsp70 or Hsp70 fragments: ABgl (del 120-428) consisting of the C-terminal part and ASma (del 438-618) consisting of the N-terminal part of human Hsp70. All antibodies reacted equally well with rHsp70 and cytoplasmic Hsp70 derived from human tumor cells or M21 rat-1 cells. Only one antibody (MA3-007; Hsp70, Hsc70) detects a region localized within the ATPase domain of Hsp70 (amino acid 122-264) and reacts positively with the C-terminal deletion mutant ASma. All other antibodies, including RPN1197 are directed against the C-terminal peptide binding domain of Hsp70 and react positively with the N-terminal deletion mutant ABgl. Although all six antibodies detect full-length Hsp70 protein, derived from plasma membrane fractions of CX+ tumor cells, cell surface expressed Hsp70 on viable CX+ tumor cells, as determined by flowcytometry, is only recognized with the antibodies MA3-006 (Hsp70, Hsc70; 504-617), MA3-009 (Hsp70; 504-617) and RPN1197 (Hsp70). An estimation of the ratio of membrane-bound to cytoplasmic Hsp70 molecules revealed that 15-20% of total Hsp70 molecules are expressed on the plasma membrane. This tumor-selective cell surface expression of Hsp70 correlates with an increased sensitivity to lysis mediated by non-MHC restricted natural killer (NK) cells. We demonstrate that only antibodies directed against membrane-bound Hsp70 (MA3-006, MA3-009, RPN1197) inhibit NK-killing activity against Hsp70-expressing tumor cells. Taken together our data indicate that at least the C-terminal

region 504-617, that contains at least one single alpha-helix (amino acid 512-536), has to be localized extracellularly and might be of importance for an NK-mediated anti-tumor immune response.

PMID: 9585177 [PubMed - indexed for MEDLINE]

Display Abstract

Show 20 Sort by Send to

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Oct 18 2005 10:52:14

DATE: Thursday, October 27, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<u>L4</u>	hsp70 same "NK cells"	29	<u>L4</u>
<u>L3</u>	hsp70 and (activate near10 cells)	719	<u>L3</u>
<u>L2</u>	hsp70 same "ex vivo"	28	<u>L2</u>
<u>L1</u>	hsp70 and ex vivo	191667	<u>L1</u>

END OF SEARCH HISTORY